Psychological Treatment of Comorbid Insomnia and Depression: A Double-Blind Randomized Placebo-Controlled Trial

被引:7
|
作者
Blom, Kerstin [1 ,2 ]
Forsell, Erik [1 ,2 ]
Hellberg, Monica [2 ]
Svanborg, Cecilia [1 ,2 ]
Jernelov, Susanna [1 ,2 ,3 ]
Kaldo, Viktor [1 ,2 ,4 ]
机构
[1] Karolinska Inst, Ctr Psychiat Res, Dept Clin Neurosci, Stockholm, Sweden
[2] Stockholm Hlth Care Serv, Stockholm, Sweden
[3] Karolinska Inst, Dept Clin Neurosci, Div Psychol, Stockholm, Sweden
[4] Linnaeus Univ, Fac Hlth & Life Sci, Dept Psychol, Vaxjo, Sweden
关键词
Insomnia; Depression; Comorbidity; Psychological treatment; Randomized controlled trial; COGNITIVE-BEHAVIORAL THERAPY; SLEEP RESTRICTION THERAPY; SELF-HELP; DSM-IV; MAJOR DEPRESSION; SOCIAL ANXIETY; FOLLOW-UP; CBT-I; METAANALYSIS; PHARMACOTHERAPY;
D O I
10.1159/000536063
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Introduction: Insomnia and depression are highly prevalent disorders and commonly occur together. Cognitive behavioral therapy for insomnia, CBT-I, has been shown to be effective in treating insomnia and also comorbid depression. However, it is unclear whether effects of CBT-I on depression are specific or nonspecific. Also, depressive symptoms often remain too high after CBT-I, indicating a need for improved treatments. The objective was to determine whether combining CBT-I with CBT for depression, without increasing treatment length, reduces both insomnia and depression more than CBT for depression with a placebo insomnia intervention. Methods: A 12-week double-blind randomized controlled trial with a 6-month follow-up in a psychiatric setting using therapist-guided internet-delivered treatments was conducted. Patients (N = 126) were diagnosed with insomnia disorder and major depression by physicians. Primary outcome measures were as follows: self-rating scales Insomnia Severity Index (ISI) and Montgomery-angstrom sberg Depression Rating Scale (MADRS-S). Results: The combined treatment showed specific effects on insomnia severity over the control treatment (p = 0.007) but was not more effective in reducing depression severity. Within-group effects (Cohen's d) at post and at 6 months were as follows: ISI 1.40 and 1.42 (combined treatment), 0.95 and 1.00 (control); MADRS-S 0.97 and 1.12 (combined), 0.88 and 0.89 (control). Conclusions: CBT-I shows large specific effects on insomnia severity and is superior to control in this regard. Both treatments had similar effects on depression severity, i.e., combining CBT-I with CBT for depression did not enhance outcomes on depression compared to control. We suggest CBT-I should always be offered to patients with insomnia and depression comorbidity, possibly as the first-hand choice. Combining it with a psychological treatment for depression could be too burdening and may not be beneficial.
引用
收藏
页码:100 / 113
页数:14
相关论文
共 50 条
  • [31] Double-blind placebo-controlled trial of fluoxetine in adolescents with comorbid major depression and an alcohol use disorder
    Cornelius, Jack R.
    Bukstein, Oscar G.
    Wood, D. Scott
    Kirisci, Levent
    Douaihy, Antoine
    Clark, Duncan B.
    ADDICTIVE BEHAVIORS, 2009, 34 (10) : 905 - 909
  • [32] Randomized double-blind pilot trial of gabapentin versus placebo to treat alcohol dependence and comorbid insomnia
    Brower, Kirk J.
    Kim, Hyungjin Myra
    Strobbe, Stephen
    Karam-Hage, Maher A.
    Consens, Flavia
    Zucker, Robert A.
    ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, 2008, 32 (08) : 1429 - 1438
  • [33] Mirtazapine in comorbid major depression and an alcohol use disorder: A double-blind placebo-controlled pilot trial
    Cornelius, Jack R.
    Chung, Tammy
    Douaihy, Antoine B.
    Kirisci, Levent
    Glance, Jody
    Kmiec, Julie
    FitzGerald, Douglas
    Wesesky, Maribeth A.
    Salloum, Ihsan
    PSYCHIATRY RESEARCH, 2016, 242 : 326 - 330
  • [34] N acetylcysteine in the treatment of alcohol use disorder: a randomized, double-blind, placebo-controlled trial
    Morley, Kirsten C.
    Peruch, Siena
    Adams, Claire
    Towers, Ellen
    Tremonti, Chris
    Watt, Joshua
    Jamshidi, Nazila
    Haber, Paul S.
    ALCOHOL AND ALCOHOLISM, 2023, 58 (05): : 553 - 560
  • [35] Acupuncture treatment of hypertension with insomnia A protocol for randomized, double-blind, placebo controlled trial research
    Zhu, Xun
    Yan, Luda
    Dou, Xuejiao
    Zheng, Yanping
    He, Guanglin
    Liao, Meiyan
    Fu, Wenbin
    MEDICINE, 2022, 101 (02) : E28455
  • [36] A double-blind, randomized, placebo-controlled plus open trial of adjunctive suvorexant for treatment-resistant insomnia in patients with bipolar disorder
    Cafaro, Rita
    Macellaro, Monica
    Suppes, Trisha
    Dell'Osso, Bernardo
    Ketter, Terence
    Ostacher, Michael
    Miller, Shefali
    Chang, Lauren
    Lyu, Jihun
    Wang, Po W.
    CNS SPECTRUMS, 2024, 29 (05) : 376 - 384
  • [37] Omega-3 fatty acids as a treatment for perinatal depression: randomized double-blind placebo-controlled trial
    Rees, Anne-Marie
    Austin, Marie-Paule
    Parker, Gordon B.
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 2008, 42 (03) : 199 - 205
  • [38] Crocus sativus L. in the treatment of mild to moderate depression:: A double-blind, randomized and placebo-controlled trial
    Akhondzadeh, S
    Tahmacebi-Pour, N
    Noorbala, AA
    Amini, H
    Fallah-Pour, H
    Jamshidi, AH
    Khani, M
    PHYTOTHERAPY RESEARCH, 2005, 19 (02) : 148 - 151
  • [39] Melatonin for sedative withdrawal in older patients with primary insomnia: a randomized double-blind placebo-controlled trial
    Lahteenmaki, Ritva
    Puustinen, Juha
    Vahlberg, Tero
    Lyles, Alan
    Neuvonen, Pertti J.
    Partinen, Markku
    Raiha, Ismo
    Kivela, Sirkka-Liisa
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 77 (06) : 975 - 985
  • [40] Flexible Dosed Duloxetine in the Treatment of Fibromyalgia: A Randomized, Double-blind, Placebo-controlled Trial
    Arnold, Lesley M.
    Clauw, Daniel
    Wang, Fujun
    Ahl, Jonna
    Gaynor, Paula J.
    Wohlreich, Madelane M.
    JOURNAL OF RHEUMATOLOGY, 2010, 37 (12) : 2578 - 2586